肾康注射液治疗早期慢性肾脏病临床观察

Clinical Observation on Shenkang Injection in the Treatment of Early Chronic Kidney Disease

目的分析早期慢性肾脏病患者采用肾康注射液治疗的临床效果。方法将2017年2月-2018年4月接受治疗的早期慢性肾脏病患者中88例设为研究对象,采用电脑随机法将其分为观察组(44例)、对照组(44例)。对照组患者接受常规西药治疗,观察组患者在接受常规治疗的同时加用肾康注射液治疗。分析2组患者的临床治疗效果以及免疫功能变化情况。结果观察组患者治疗有效率显著高于对照组(P<0.05);治疗后2组患者的24h蛋白尿定量、Scr、BUN水平均显著低于治疗前(P<0.05),且观察组患者的24h蛋白尿定量、Scr、BUN水平均显著低于对照组(P<0.05)。结论临床上针对早期慢性肾脏病患者采用肾康注射液效果良好,有利于提升患者的免疫功能,具有临床推广价值。

Objective To analyze the clinical effect of Shenkang injection in the treatment of early chronic kidney disease and the effect of improving immune function. Methods 88 cases of early chronic kidney disease treated in our hospital from February 2017 to April2018 were studied. The patients were divided into observation group(44 cases) and control group(44 cases) by computer random method. The control group was treated with routine western medicine. The observation group was treated with Shenkang injection on the basis of routine treatment. The curative effect and immune function of the two groups were analyzed. Results The effective rate of the observation group was significantly higher than that of the control group(P<0.05). After treatment, 24-hour proteinuria quantification, Scr and BUN levels in both groups were significantly lower than those before treatment(P <0.05). The 24-hour proteinuria quantification, Scr and BUN levels in the observation group were significantly lower than those in the control group(P<0.05). Conclusion The effect of Shenkang injection on early chronic kidney disease is good. It is helpful to improve immune function and has popularization value.